Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUS) in Chennai, India

Indian Journal of Medical Research

Volumn 132, Issue 12, 2010, Pages 706-714

  Mehta, Shruti H ^a   Vogt, Samantha L ^a   Srikrishnan, Aylur K ^b   Vasudevan, Conjeevaram K ^b   Murugavel, Kalilapuri G ^b   Saravanan, Shanmugam ^b   Anand, Santhanam ^b   Suresh Kumar, M ^b   Ray, Stuart C ^a   Celentano, David D ^a   Solomon, Suniti ^b   Solomon, Sunil S ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

Author keywords

APRI; HCV genotype; Hepatitis C virus; HIV; Injection drug users; Liver disease

Indexed keywords

ASPARTATE AMINOTRANSFERASE; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY TITER; ARTICLE; CANNABIS ADDICTION; FEMALE; FOLLOW UP; GENOTYPE; GROUPS BY AGE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INDIA; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIXED INFECTION; PERSISTENT VIRUS INFECTION; RNA SEQUENCE; TATTOO; THROMBOCYTE; VIROLOGY; BLOOD; COHORT ANALYSIS; DRUG USE; GENETICS; LIVER CIRRHOSIS; NONPARAMETRIC TEST; PREVALENCE; PROSPECTIVE STUDY; STATISTICS;

ADULT; ANTIBODIES, VIRAL; ASPARTATE AMINOTRANSFERASES; BLOOD PLATELETS; COHORT STUDIES; DRUG USERS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INDIA; LIVER CIRRHOSIS; MALE; PREVALENCE; PROSPECTIVE STUDIES; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 78751500947     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-8.
2. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992; 327: 1906-11.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
4. Benhamou Y, Bochet M, Di MV, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.
5. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-91.
6. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-45.
7. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect 2006; 82 (Suppl 3): 10-7.
8. Kumar MS, Mudaliar S, Thyagarajan SP, Kumar S, Selvanayagam A, Daniels D. Rapid assessment and response to injecting drug use in Madras, south India. Int J Drug Policy 2000; 11: 83-98.
9. Mahanta J, Medhi GK, Paranjape RS, Roy N, Kohli A,Akoijam BS, et al. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India. AIDS 2008; 22 (Suppl 5): S59-68.
10. Jain M, Chakravarti A, Verma V, Bhalla P. Seroprevalence of hepatitis viruses in patients infected with the human immunodeficiency virus. Indian J Pathol Microbiol 2009; 52: 17-9.
11. Solomon SS, Hawcroft CS, Narasimhan P, Subbaraman R, Srikrishnan AK, Cecelia AJ, et al. Co-morbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res 2008; 127: 447-52.
12. Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: A cause for concern.J Acquir Immune Defic Syndr 2008; 49: 327-32.
13. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698-707.
14. Behrens T, Taeger D, Wellmann J, Keil U. Different methods to calculate effect estimates in cross-sectional studies. A comparison between prevalence odds ratio and prevalence ratio. Methods Inf Med 2004; 43: 505-9.
15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
16. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-83.
17. Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, et al. High incidence of mortality in a cohort of HIV positive and negative injection drug users in Chennai, India. XVII International AIDS Conference, Mexico City, Mexico; 2008.
18. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T- lymphotropic viruses. Am J Public Health 1996; 86: 655-61.
19. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.
20. Solomon SS, Celentano D, Srikrishnan A, Vasudevan C, Mrurgavel K, Thanburaj E, et al. Low HIV incidence and declining risk behaviors in a cohort of injection drug users in Chennai, India. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA; 2008.
21. Tseng FC, Edlin BR, Zhang M, Kral A, Busch MP, Ortiz-Conde BA, et al. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat 2008; 15: 690-8.
22. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71.
23. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-55.
24. Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 2006; 29 (Suppl 3): 58-65.
25. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-9.
26. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
27. Kochar DK, Agarwal P, Kochar SK, Jain R, Rawat N, Pokharna RK, et al. Hepatocyte dysfunction and hepatic encephalopathy in Plasmodium falciparum malaria. QJM 2003; 96: 505-12.
28. Itha S, Kashyap R, Krishnani N, Saraswat VA, Choudhuri G, Aggarwal R. Profile of liver involvement in dengue virus infection. Natl Med J India 2005; 18: 127-30.
29. Caregaro L, Alberino F, Amodio P, Merkel C, Bolognesi M, Angeli P, et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996; 63: 602-9.
30. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.